Jonathan Campbell, PhD: Value-Based Contracts and Biosimilars

Jonathan Campbell, PhD, associate professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado, discusses whether value-based contracts have a role to play in biosimilar uptake.


For biosimilars, outcomes-base contracting may be very important in terms of guarantees for certain health outcomes, like a measure of response of the patient. So that could be certainly something in a broad understanding of value that’s very interesting, so it could certainly apply to biosimilars as well.